Pub Date : 2023-09-01DOI: 10.1089/ct.2023;35.350-354
Laura Boucai, Ashish Chintakuntlawar, David C. Shonka
Clinical Thyroidology®Vol. 35, No. 9 EditorialFree AccessA Summary of State-of-the-Art Clinical Trials for Advanced Thyroid Cancers, Organized by the International Thyroid Oncology GroupLaura Boucai, Ashish Chintakuntlawar, David C. Shonka, Jr., and Members, ITOGLaura Boucai Division of Subspecialty Medicine, Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, U.S.A.Search for more papers by this author, Ashish Chintakuntlawar Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, U.S.A.Search for more papers by this author, David C. Shonka, Jr. Department of Otolaryngology—Head & Neck Surgery, University of Virginia Health System, Charlottesville, Virginia, U.S.A.Search for more papers by this author, and Members, ITOGPublished Online:13 Sep 2023https://doi.org/10.1089/ct.2023;35.350-354AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail This invited editorial provides a summary of the history and mission of the International Thyroid Oncology Group (ITOG), highlighting the continuing collaboration between Clinical Thyroidology and ITOG.The International Thyroid Oncology Group (ITOG, www.itog.org) is a not-for-profit organization founded in 2006 whose mission is to find a cure for the most challenging thyroid cancers. The group does this through the collaborative efforts of a multidisciplinary team of endocrinologists, surgeons, medical and radiation oncologists, basic scientists, and advocates by designing, coordinating, and prioritizing state-of-the-art clinical trials and correlative science studies.The organization grew out of a need for novel treatments in advanced thyroid cancer and was ultimately inspired by thyroid cancer patients such as Ms. Jean Vicks—a mother, a coach, and an avid outdoor enthusiast. After the initial meeting in 2003, the organization's inception was formalized at an inaugural meeting in Atlanta, Georgia, in 2006. The founding members included Drs. Robert Gagel, Samuel Wells, Jr., and Steven Sherman and Mr. Dwight Vicks. Since then, ITOG's membership has grown to include prominent scientists and leading clinicians in the field of thyroid cancer.Currently, ITOG's membership includes 132 leading physicians, scientists, and advocates from 16 countries: Australia, Brazil, Canada, China, France, Germany, Israel, Italy, the Netherlands, Saudi Arabia, Singapore, South Korea, Spain, Switzerland, the United Kingdom, and the United States. ITOG is organized into 12 committees and 7 task forces that work toward the common goal of finding new therapies for thyroid cancer, training the next generation of clinicians and scientists, and raising public awareness about the importance of thyroid cancer research.Through the tireless efforts and commitment of its members and advocates, ITOG has successfully completed seven clinical trials (Table 1). The
{"title":"A Summary of State-of-the-Art Clinical Trials for Advanced Thyroid Cancers, Organized by the International Thyroid Oncology Group","authors":"Laura Boucai, Ashish Chintakuntlawar, David C. Shonka","doi":"10.1089/ct.2023;35.350-354","DOIUrl":"https://doi.org/10.1089/ct.2023;35.350-354","url":null,"abstract":"Clinical Thyroidology®Vol. 35, No. 9 EditorialFree AccessA Summary of State-of-the-Art Clinical Trials for Advanced Thyroid Cancers, Organized by the International Thyroid Oncology GroupLaura Boucai, Ashish Chintakuntlawar, David C. Shonka, Jr., and Members, ITOGLaura Boucai Division of Subspecialty Medicine, Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, U.S.A.Search for more papers by this author, Ashish Chintakuntlawar Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, U.S.A.Search for more papers by this author, David C. Shonka, Jr. Department of Otolaryngology—Head & Neck Surgery, University of Virginia Health System, Charlottesville, Virginia, U.S.A.Search for more papers by this author, and Members, ITOGPublished Online:13 Sep 2023https://doi.org/10.1089/ct.2023;35.350-354AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail This invited editorial provides a summary of the history and mission of the International Thyroid Oncology Group (ITOG), highlighting the continuing collaboration between Clinical Thyroidology and ITOG.The International Thyroid Oncology Group (ITOG, www.itog.org) is a not-for-profit organization founded in 2006 whose mission is to find a cure for the most challenging thyroid cancers. The group does this through the collaborative efforts of a multidisciplinary team of endocrinologists, surgeons, medical and radiation oncologists, basic scientists, and advocates by designing, coordinating, and prioritizing state-of-the-art clinical trials and correlative science studies.The organization grew out of a need for novel treatments in advanced thyroid cancer and was ultimately inspired by thyroid cancer patients such as Ms. Jean Vicks—a mother, a coach, and an avid outdoor enthusiast. After the initial meeting in 2003, the organization's inception was formalized at an inaugural meeting in Atlanta, Georgia, in 2006. The founding members included Drs. Robert Gagel, Samuel Wells, Jr., and Steven Sherman and Mr. Dwight Vicks. Since then, ITOG's membership has grown to include prominent scientists and leading clinicians in the field of thyroid cancer.Currently, ITOG's membership includes 132 leading physicians, scientists, and advocates from 16 countries: Australia, Brazil, Canada, China, France, Germany, Israel, Italy, the Netherlands, Saudi Arabia, Singapore, South Korea, Spain, Switzerland, the United Kingdom, and the United States. ITOG is organized into 12 committees and 7 task forces that work toward the common goal of finding new therapies for thyroid cancer, training the next generation of clinicians and scientists, and raising public awareness about the importance of thyroid cancer research.Through the tireless efforts and commitment of its members and advocates, ITOG has successfully completed seven clinical trials (Table 1). The ","PeriodicalId":72629,"journal":{"name":"Clinical thyroidology","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135298063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：